Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772884 | 0.86 | MAPK1 (0.40) | NNMTMAPK1ATMCRBNKDM4E | |
| SCHEMBL30903478 | 0.85 | CRBN (0.37) | NNMTMAPK1ATMCRBNKDM4E | |
| SCHEMBL21772859 | 0.85 | CRBN (0.37) | NNMTMAPK1ATMCRBNKDM4E | |
| SCHEMBL21783039 | 0.85 | NNMT (0.42) | NNMTMAPK1CRBNKDM4EMAPT | |
| SCHEMBL30903477 | 0.82 | OPRM1 (0.38) | NNMTMAPK1CRBNKDM4EL3MBTL1 | |
| SCHEMBL21772873 | 0.82 | OPRM1 (0.38) | NNMTMAPK1CRBNKDM4EL3MBTL1 | |
| SCHEMBL25311098 | 0.78 | CRBN (0.52) | NNMTCRBN | |
| SCHEMBL13332908 | 0.77 | NNMT (0.66) | NNMTMAPK1ATMKDM4EL3MBTL1 | |
| SCHEMBL21783035 | 0.77 | NNMT (0.45) | NNMTCRBNKDM4EMAPTALDH1A1 | |
| SCHEMBL20722588 | 0.75 | NNMT (0.68) | NNMTMAPK1ATMKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | NNMT 2142/4885MAPK1 2584/4885ATM 4674/4885 |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | NNMT 2142/4885MAPK1 2584/4885ATM 4674/4885 |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | NNMT 2142/4885MAPK1 2584/4885ATM 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.